Autres langues AB Science

Actions

AB

FR0010557264

Produits pharmaceutiques

PEA

PEA/PME

Marché Fermé - Euronext Paris 17:55:00 25/08/2026			Après clôture 19:24:22
0,7390 ^EUR	+9,97 %		0,7380	-0,14 %

17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé

Autres langues

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
10/08	AB Science Wraps Up EUR14 Million Private Placements
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development
07/07	AB Science S.A. Announces Board Changes
07/07	AB Science S.A. Announces CEO Changes
03/07	AB Science S.A. announced that it has received $2.01616 million in funding
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
18/06	AB Science Secures US Patent for Prostate Cancer Therapy
17/06	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042
09/06	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
02/06	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
26/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share
25/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
18/05	AB Science S.A. announced that it has received $2.989368 million in funding
13/05	AB Science : Annual financial results as of 31 December, 2025